Management ChangeMay 4, 2026, 06:02 AM
Aura Biosciences Appoints Natalie Holles CEO; Phase 3 Trial Nears Completion
AI Summary
Aura Biosciences announced the appointment of Natalie Holles as its new Chief Executive Officer, President, and a member of the Board of Directors, effective April 30, 2026. Ms. Holles, a seasoned industry executive with rare disease commercialization experience, succeeds company founder Elisabet de los Pinos. Concurrently, the company provided an update on its Phase 3 CoMpass trial for belzupacap sarotalocan, stating that enrollment is nearing completion with 86 patients enrolled and over 25 more identified for screening, maintaining guidance for enrollment completion by mid-2026 and topline data in the second half of 2027.
Key Highlights
- Natalie Holles appointed Chief Executive Officer, President, and Board member, effective April 30, 2026.
- Ms. Holles succeeds founder Elisabet de los Pinos, Ph.D.
- Phase 3 CoMpass trial for belzupacap sarotalocan is nearing enrollment completion.
- 86 patients have been enrolled in the study as of May 4, 2026.
- Over 25 additional patients are scheduled or identified for screening through May 2026.
- Enrollment completion is reiterated for mid-2026.
- Topline data from the CoMpass trial is anticipated in the second half of 2027.